Preclinical Pharmacology Services to Support Evaluation of Novel Cell & Gene Therapies
Speaker: Leila Kokabee, Ph.D, Senior Scientist II & Study Director, Preclinical Pharmacology in Biocytogen Boston Cell and gene therapies aim to treat diseases through the restoration or alteration of certain sets of cells, or by using cells to carry a therapy through the body. While cell therapies typically use engineered CAR-T or CAR-NK cells to […]
Read moreMaximize Your Drug Design Possibilities with RenNano-derived Fully Human Nanobodies
Speaker: Yi (Benny) Yang, PhD. Chief Scientific Officer, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Compared to traditional antibodies, nanobodies are significantly smaller in size, which is advantageous for penetrating tumors and crossing the blood-brain barrier. The protruding CDR3 regions of nanobodies make them better at targeting hidden epitopes, and their simple structure makes them ideal for […]
Read moreGeneration of TCR-mimic antibodies targeting intracellular proteins to expand the druggable target repertoire for anti-tumor therapies
Speaker: W. Frank An, PhD. Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals Traditional antibody therapy has been limited to extracellular tumor targets; however, many oncogenic and tumor-associated proteins are intracellular. One strategy to overcome this limitation is to target the pHLA complex mimicking TCR recognition. In this webinar, Dr. W. Frank […]
Read morePredicting Toxicity of Immuno-Oncology Drug Candidates: Preclinical Platforms to Evaluate Toxicology In Vivo and Ex Vivo
Speaker: Jenna Frame, Ph.D. Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston Corp Therapeutics targeting the immune system for oncology applications (such as immune checkpoint inhibitors, or ICIs) can in some cases lead to adverse effects in patients, and may affect multiple organ systems and/or cause CRS (cytokine release syndrome). Thus, predicting the safety and […]
Read moreOvercoming Difficulties In GPCR Antibody Discovery Using Biocytogen’s Renmice-Based Platform
Speaker: Yanan Guo, Ph.D. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals GPCRs (G protein-coupled receptor) are the most abundant membrane protein in the human genome, and are targeted by approximately one-third of drugs on the market. However, the difficulty in antigen preparation and novel GPCR-targeting antibody screening has posed significant challenges […]
Read moreBispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety
Speaker: W. Frank An, PhD. Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals Bispecific ADCs (BsADCs) are emerging as a promising modality in anti-cancer therapies. BsADCs offer increased target diversity and selectivity from the dual targeting antibody moiety, in combination with the targeted delivery of cytotoxic payloads for potent tumor cell killing. […]
Read moreWebinar Categories
- Humanized Animal Models
- Others
- Renbiologics